

Allergy Therapeutics^{PLC}

Allergy Therapeutics plc
("Allergy Therapeutics", "ATL" or the "Group")

Allergy Therapeutics and EAACI announce winner of EAACI Early Career Research Award

10 June 2025 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, in collaboration with the European Academy of Allergy and Clinical Immunology (EAACI), today announces the winner of the EAACI Early Career Research Award.

The EAACI Early Career Research Award encourages young researchers and clinicians to push the boundaries in allergen immunotherapy research that can contribute to advancing allergy and immunology research and innovation, as future leaders in the field. The recipient of this year's award is Dr. Janice Layhadi, who is an early career researcher in the field of biomarker discovery in allergen immunotherapy.

Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, said: "We are proud to support the EAACI Early Career Research Award and wish to congratulate the winner, Dr. Janice Layhadi, a rising star whose research is at the forefront of allergy and immunology research. Encouraging the next generation of researchers is vital to advancing our understanding of allergy and translating innovation into new therapeutic approaches that can meaningfully improve the lives of people living with allergies. Together with EAACI and through this award, we are committed to fostering scientific excellence that we hope will shape the future of allergy research and, ultimately, transform outcomes for patients."

Maria Jose Torres, President of the European Academy of Allergy and Clinical Immunology, said: "I would like to congratulate Dr. Janice Layhadi and extend my thanks to all the young researchers and clinicians for their applications this year. Recognising and supporting early-career researchers is fundamental to the advancement of the allergy research field and central to EAACI's mission. This award reinforces our commitment to fostering innovation, empowering the next generation of scientists and improving patient care."

Dr. Layhadi is a Research Associate at the Immunomodulation and Tolerance Group (ITG) of Allergy & Clinical Immunology, at Imperial College London's National Heart and Lung Institute. She completed her undergraduate studies in Biochemistry at Imperial College London and pursued a Master's degree in Pharmacology at Oxford University. Dr. Layhadi completed her PhD studies in molecular sciences and pharmacology at the University of East Anglia in 2017 and joined Professor Mohamed Shamji's group at Imperial College London. Her research interest primarily involves identifying underpinning molecular mechanisms that are induced following allergen immunotherapy and correlate with clinical efficacy.

Dr. Janice Layhadi said: "I am truly honoured to be the inaugural recipient of the EAACI Early Career Research Award. This recognition is both humbling and motivating, as it provides essential seed funding to generate the preliminary data critical for securing independent research support. With this award, I will continue to advance my investigations into the cellular and molecular mechanisms influenced by allergen-specific immunotherapy, using a comprehensive multi-omic approach. These opportunities are instrumental in supporting my transition to research independence."

The EAACI Early Career Research Award provides an unrestricted research grant of up to €30,000 and is open to EAACI Junior Members who have previously published their high-impact research on allergy and immunology and demonstrated their drive and dedication in the area of immunotherapy. The planned research is expected to contribute to a better understanding of allergic inflammation as well as improved diagnostic procedures and treatment, enabling improved patient management and patient satisfaction.

The award will be presented to Dr. Layhadi by Maria Jose Torres, President of EAACI, Mohamed Shamji, Secretary General of EAACI, Matthias Kramer, International Medical Director at Allergy Therapeutics, and Anke Graessel, Principal Medical Advisor Corporate at Allergy Therapeutics, at the opening ceremony of the EAACI Annual Congress 2025, Glasgow, UK, on Friday, 13 June. The congress will run until 16 June.

- ENDS -

Allergy Therapeutics
Manuel Llobet, Chief Executive Officer
Shaun Furlong, Chief Financial Officer
+44 (0)1903 845 820

Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash / Giles Balleny / Seamus Fricker
Nigel Birks - Life Science Specialist Sales
Tamar Cranford Smith - Sales
+44 (0)20 7220 0500

ICR Healthcare
Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700
allergytherapeutics@icrhealthcare.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRASFDSMSEISESM